Abstract: Antacid powders, tablets etc. of prolonged gastric residence time have an internal phase of a solid antacid and excipient surrounded by a solid external phase containing a hydrophobic substance e.g. an ester of glycerol with palmitic or stearic acid, a hydroxylated polyalkene and a non-ionic emulsifier.

Abstract: A method of treating anxiety including administering to a person to be treated an effective amount of compounds of the general formula: ##STR1## wherein the various substituents are defined hereinbelow have pharmacological properties rendering them useful as antiemetic agents with reduced undesirable side-effects or as anxiolytic agents. Various methods are described for their preparation involving formation of the amide link, etherification of the 2-hydroxy derivative, introducing the R.sup.5 CH.sub.2 group on the N-unsubstituted azabicyclooctane or nonane or, for 4-amino compounds, by hydrolysing a 4-acylamino derivative.

Abstract: Compounds of the general formula: ##STR1## wherein the various substituents are defined hereinbelow have pharmacological properties rendering them useful as antiemetic agents with reduced undesirable side-effects. Various methods are described for their preparation involving formation of the amide link, etherification of the 2-hydroxy derivative, introducing the R.sup.5 CH.sub.2 group on the N-unsubstituted azabicyclooctane or nonane or, for 4-amino compounds by hydrolysing a 4-acylamino derivative.

Abstract: Substituted benzamides of the general formula I ##STR1## in which: R represents an alkoxy, alkenyloxy or alkynyloxy group containing up to 7 carbon atoms in the group,R.sub.1 is hydrogen or a NR.sub.4 R.sub.5, or NR.sub.6 COR.sub.7 group, where R.sub.4, R.sub.5 and R.sub.6, which may be the same or different, is each hydrogen or an alkyl group and R.sub.7 is an alkyl or trifluoromethyl group,R.sub.2 is hydrogen, halogen, or a nitro, or sulphamoyl group,R.sub.3 represents hydrogen or a methyl or methoxy group,X represents a hydrocarbon chain containing 1 to 4 carbon atoms, one of which may optionally be replaced by an oxygen atom,Y represents a non-aromatic cyclic ether or a non-aromatic cyclic thioether group and pharmaceutically acceptable salts thereof are useful in the treatment of gastro-intestinal disorders. Various methods of synthesis are described including synthesis via novel amines of the formula ##STR2## which are themselves obtained by reduction of the corresponding oximes.

Abstract: A process for producing basic aluminum magnesium carbonate, Al.sub.2 Mg.sub.6 (OH).sub.14 (CO.sub.3).sub.2.4H.sub.2 O, by carbonating an aluminum hydroxide (Al(OH).sub.3) and magnesium hydroxide aqueous reaction mixture with carbon dioxide in the presence of at least 6 moles of a base selected from the group consisting of ammonia, mono, di or trialkylamines, pyridine or piperidine, per mole of Al.sub.2 O.sub.3 present. The product is useful as an antacid.

Abstract: Compounds of the general formula I: ##STR1## wherein R.sup.1 represents a thienyl group, or a phenyl group optionally substituted by a halogen (preferably fluorine or chlorine) atom, a lower alkoxy or lower alkyl group, R.sup.2 represents a hydrogen or halogen (preferably fluorine) atom, a lower alkoxy or lower alkyl group, R.sup.3 represents a hydrogen or halogen (preferably fluorine) atom, a lower alkylthio, lower alkoxy or lower alkyl group, or a cycloalkyl group containing 5 or 6 carbon atoms, or a group of the general formula: ##STR2## wherein R.sup.4 and R.sup.5 singly each represents a hydrogen atom or lower alkyl group, R.sup.6 represents a cycloalkyl, hydroxymethyl, carboxy or lower alkoxycarbonyl group, and W represents a carbonyl ##STR3## or a hydroxymethylene [viz. --CH(OH)--] group, and pharmacologically acceptable salts thereof possess potent selective Histamine H.sub.

Abstract: A new basic aluminium magnesium carbonate of the formula Al.sub.2 Mg.sub.6 (OH).sub.14 (CO.sub.3).sub.2.4H.sub.2 O has been found to be useful in pharmaceutical formulations for the treatment of upper gastrointestinal tract disturbances associated with excess acid and pepsin secretion or biliary reflux.

Abstract: This invention relates to new therapeutically useful piperidine derivatives and salts thereof. The invention also relates to processes for their preparation and pharmaceutical compositions containing them.

Abstract: This invention relates to piperidine derivatives. More particularly, the invention relates to substituted benzoic acid amides of N-substituted piperidine and to pharmaceutical compositions thereof, which are useful in antagonizing the effects of dopamine or dopaminergic agents of endogenous or exogenous origin and in treating nausea and vomiting resulting from gastrointestinal disorders, congestive heart failure, post operative conditions, etc., other gastrointestinal disorders such as dyspepsia, flatulence, bile regurgitations, hiatus hernia, peptic ulcer, reflux aerophagitis, gastritis, duodenitis, and cholethiasis, and a variety of conditions affecting the central nervous system such as acute and chronic psychoses, maniacal psychosis, schizophrenias, serious disturbances of behavior and non-melancholic depressive state and migraine. The invention also relates to methods of preparing piperidine derivatives.